Apolipoprotein assay kit B003 series

for liver diseasefor kidney diseasefor cardiovascular diseases

This kit is used to quantitatively detect the content of apolipoprotein A1 (ApoA1) in human serum in vitro. Background of Clinical Indications It is used for the auxiliary diagnosis of coronary heart disease and cerebrovascular disease. ApoA1 is an anti-atherosclerosis indicator. Its decrease can be seen in patients with nephrotic syndrome, active hepatitis, liver parenchymal damage, and diabetes, etc. ApoA1 (together with ApoA2) accounts for 80% to 90% of HDL protein. Therefore, ApoA1 in serum can represent the level of HDL, which is obviously positively correlated with HDL-C. ApoA1 is low in patients with coronary heart disease and cerebrovascular disease, and ApoA1 is extremely low in serum of patients with ApoA1 deficiency, clustered hypo-α lipoproteinemia, and fisheye disease. HDL-C is often low in patients with cluster hypertriglyceridemia, but ApoA1 is not necessarily low, which does not increase the risk of coronary heart disease.